Novo Nordisk , looking to turn around slowing growth of its blockbuster weight-loss drug Wegovy, plans to test whether its ...

Novo Nordisk plans to examine in clinical trials whether its future weight-loss drugs can treat a wide range of health ...

It's not as flashy as the other Apple Watches in this year's lineup, but the SE 3 will make a strong case for many buyers.

The SE 3 is the most affordable model in Apple’s latest smartwatch lineup. Featuring a 100% recycled aluminum case, it's ...

The fundamentals of the industry are driven by demographics, and broadening the scope provides a bit of growth opportunity,' ...

STORY: Novo Nordisk will test whether its future weight-loss drugs can treat a wide range of obesity-linked conditions. It’s already begun doing so with its blockbuster drug Wegovy. The Danish ...

A new generation of Alzheimer’s blood tests could speed up diagnosis and access to care—but they also raise thorny questions ...

An investigational small-molecule, nonpeptide oral GLP-1 receptor agonist significantly reduced weight in adults with obesity in the randomized ATTAIN-1 trial. At week 72, orforglipron at multiple ...

Starting at $399, the Series 11 is the middle option in Apple’s smartwatch lineup. The Apple Watch SE 3 (starting at $249) is ...

A new study suggests that treating insomnia could help protect against future cognitive decline. Here’s what to know.